Bayer, CRISPR Therapeutics Launch JV to Develop CRISPR/Cas9 Treatments

Dec 21, 2015

|

NEW YORK (GenomeWeb) – Switzerland's CRISPR Therapeutics and Germany's Bayer today announced a yet unnamed joint venture to develop ways to deliver CRISPR/Cas9 genome editing in a clinical setting.

The deal brings together Bayer's experience in protein engineering and knowledge of human diseases with CRISPR Therapeutics' CRISPR/Cas9 intellectual property and genome editing expertise, the firms said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Sharing, But Kinda Sorta

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

This Week in Science

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

Structural Biologist Leads India's CSIR

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

Upward of One Hundred

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Main menu